![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. | ![]() Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| ![]() Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | ![]() Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. | ![]() Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | ![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 | Founding Date 2010 | Founding Date 2000 | Founding Date 2007 | Founding Date 1980 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations San Diego, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations Carlsbad, US HQ | ||
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 17 | Employees 31019% decrease | Employees 5,60044% increase | Employees 999 | Employees 2462% decrease | Employees 1,31413% increase | Employees 92716% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 6.6 b | Valuation ($) 11.8 m | Valuation ($) 1.5 m | Valuation ($) 21.2 b | Valuation ($) 648.3 m | Valuation ($) 105.4 m | Valuation ($) 12.4 b | Valuation ($) 6.3 b |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $6.8b (FY, 2023) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $1.2b (FY, 2023) | Revenue (est.) $787.6m (FY, 2023) |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods $4.7b (FY, 2023) | Cost of goods €64.3m (FY, 2023) | Cost of goods N/A | Cost of goods $150.3m (FY, 2023) | Cost of goods $9.1m (FY, 2023) |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit $2.2b (FY, 2023) | Gross profit (€2.6m) (FY, 2023) | Gross profit N/A | Gross profit $1.1b (FY, 2023) | Gross profit $778.5m (FY, 2023) |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income ($4.7b) (FY, 2023) | Net income (€260.2m) (FY, 2023) | Net income ($30m) (FY, 2023) | Net income ($536m) (FY, 2023) | Net income ($366.3m) (FY, 2023) |
Operating ⚠ | |||||||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications 430 (FY, 2021) | Patent Applications 500 (Mar, 2020) | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A |
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued 270 (FY, 2020) | Patents Issued 233 (May, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 13 (FY, 2023) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2023) |
Funding | |||||||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.8b | Total funding raised $ 1.1b | Total funding raised $ 10m | Total funding raised N/A | Total funding raised N/A |
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyCelyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyModerna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View company